Vasomotor symptoms are the most commonly reported symptoms of menopause. Vasomotor symptoms are usually described as hot flashes, night sweats, and flushes. In addition, these symptoms are characterized by a sudden increase in blood flow to the neck, face, and chest, which causes profuse sweating. These symptoms can even cause a disturbed sleep pattern when they occur at night. In totality, vasomotor symptoms vary greatly in their frequency and intensity among menopausal women and are most debilitating in the first two years of menopause. However, for some women, the symptoms can be persistent indefinitely
COVID-19 Impact Analysis
COVID-19 is an infectious disease that originated in the Hubei province of the Wuhan city in China in December, 2019. The highly contagious disease, caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is transmitted from human to human. Since its outbreak, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing a shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness significant growth in the future, owing to the demand for vaccines and treatment drugs for COVID-19.
However, with COVID-19, the supply chain of the raw materials required to manufacture therapeutic hormones for vasomotor symptoms has been disrupted in many countries. In addition, the market growth of pharmaceuticals is also declining as the manufacturers of drugs have slowed down their production because of the pandemic. This, in turn, is expected to have a significant impact on the vasomotor symptoms market.
Top Impacting Factors
There is a rise in the number of organizations investing in R&D and clinical trial candidates. This is acting as a major factor for the growth of the vasomotor symptoms market.
Increase in product launches by prominent players in the vasomotor symptoms market is expected to boost the market growth. For instance, in 2019, Otsuka Pharmaceutical launched EQUELLE. EQUELLE is a non-hormonal and non-prescription supplement that helps alleviate the frequency of muscle aches and hot flashes associated with menopause in the U.S.
In developing countries, the awareness regarding menopause and vasomotor symptoms has increased. With rise in awareness, people are open to seek better and advanced treatment options for their conditions.
However, the complications and side-effects associated with treatment options for vasomotor symptoms can reduce the growth of the vasomotor symptoms market. For instance, hormone replacement therapy can cause side effects such as bloating, bleeding, headaches, breast enlargement or tenderness, nausea, and mood changes in women.
Key Market Trends
In 2020, KaNDy Therapeutics received positive data from its ‘SWITCH-1’ clinical trial with its non-hormonal drug candidate NT-814. It helps treat vasomotor symptoms of menopause. Similarly, Radius Pharma has its drug Elacestrant (RAD1901) which can potentially be used in hormone-resistant or hormone-driven breast cancer, and menopause-related vasomotor symptoms in postmenopausal women.
North America holds a major market share of vasomotor symptoms owing to the presence of major players such as Eli Lilly Company and TherapeuticsMD, Inc. These companies have established their clientele in Latin American as well as North American countries.
The European region also holds a significant share of the vasomotor symptoms market. This can be attributed to the increase in various clinical trial studies in European countries. For instance, in 2020, Mithra Pharmaceuticals updated its E4 Comfort clinical program which aimed at enrolling 2200 menopausal women.
Asia-Pacific is predicted to be the fasted growing region in the vasomotor symptoms market. Prominent players are employing many strategic activities like mergers and acquisitions. For instance, in 2017, Mithra Pharmaceuticals signed a license and agreement with Fuji Pharma to commercialize Donesta in Japan.
Key Benefits of the Report
- This study presents the analytical depiction of the vasomotor symptomsindustry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the vasomotor symptomsmarket share.
- The current market is quantitatively analyzed to highlight the growth scenario of the vasomotor symptoms market.
- Porter’s five forces analysis illustrates the potency of buyers and suppliers in the market.
- The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.
Questions Answered in the Vasomotor Symptoms Report
- Which are the leading players active in the vasomotor symptoms market?
- How is each segment of the market expected to grow during the forecast period?
- What are the adoption trends for the vasomotor symptoms market in emerging economies and established economies across the world?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What future projections would help in taking further strategic steps in the market?
Vasomotor Symptoms Market Report Highlights
| Aspects | Details |
 By Therapy Type |
|
 By End User |
|
 By Distribution Channel |
|
 By Region |
|
 Key Market Players | Procter and Gamble, Novo Nordisk A/S, Mithra Pharmaceuticals, Merck and Co., Inc., Pfizer Inc., Eli Lily and Company, Emcure Pharmaceuticals Ltd., TherapeuticsMD, Inc., Teva Pharmaceuticals, Novartis AG |
Loading Table Of Content...
